Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Ambient Light Multiple Myeloma Study

NCT: NCT05737732 · RECRUITING

NCT IDNCT05737732
StatusRECRUITING
Start Date2023-02-13
Completion2027-06-30
SponsorIcahn School of Medicine at Mount Sinai (OTHER)
First posted
Last updated

Brief Summary

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.

Frequently Asked Questions

What is The Ambient Light Multiple Myeloma Study?

The Ambient Light Multiple Myeloma Study is a clinical trial registered under NCT05737732. Current status: RECRUITING.

What is the status of NCT05737732?

The current status of NCT05737732 (The Ambient Light Multiple Myeloma Study) is: RECRUITING.

When did The Ambient Light Multiple Myeloma Study start?

The Ambient Light Multiple Myeloma Study started on 2023-02-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.